Pages without language links

Jump to navigation Jump to search

The following pages do not link to other language versions.

Showing below up to 50 results in range #4,401 to #4,450.

View (previous 50 | next 50) (20 | 50 | 100 | 250 | 500)

  1. Section 1: Introduction (from DOI: 10.1007/s11886-020-01292-3)
  2. Section 1: Introduction (from DOI: 10.1007/s11886-020-01293-2)
  3. Section 1: Introduction (from DOI: 10.1016/j.adro.2020.04.015)
  4. Section 1: Introduction (from DOI: 10.1016/j.clim.2020.108427)
  5. Section 1: Introduction (from DOI: 10.1016/j.jcv.2020.104372)
  6. Section 1: Introduction (from DOI: 10.1038/s41392-020-0110-5)
  7. Section 1: Introduction (from DOI: 10.1080/22221751.2020.1735265)
  8. Section 1: Introduction (from DOI: 10.1084/jem.20200653)
  9. Section 1: Introduction (from DOI: 10.1186/s13054-020-02882-x)
  10. Section 1: Introduction (from DOI: 10.3201/eid2605.200146)
  11. Section 2.1: Biological characteristics of CSCs (from DOI: 10.1038/s41392-020-0110-5)
  12. Section 2.1: Lessons from animal models (from DOI: 10.1016/j.jcv.2020.104372)
  13. Section 2.1: Selection of front-line personnel (from DOI: 10.1080/22221751.2020.1735265)
  14. Section 2.2: Congenital and perinatal infections with coronaviruses other than SARS-CoV-2 (from DOI: 10.1016/j.jcv.2020.104372)
  15. Section 2.2: Isolation and identification of CSCs (from DOI: 10.1038/s41392-020-0110-5)
  16. Section 2.2: Isolation and protection requirements (from DOI: 10.1080/22221751.2020.1735265)
  17. Section 2.3: Congenital and perinatal infections with SARS-CoV-2 (from DOI: 10.1016/j.jcv.2020.104372)
  18. Section 2.3: Isolation and observation of medical personnel after close contact with SARS-CoV-2 (from DOI: 10.1080/22221751.2020.1735265)
  19. Section 2. Traditional Methods of Diagnosing Infections (from DOI: 10.3390/v12020211)
  20. Section 2: Biology of SARS-CoV-2 (from DOI: 10.1007/s11886-020-01292-3)
  21. Section 2: COVID-19: Potential factors contributing to ICU delirium (from DOI: 10.1186/s13054-020-02882-x)
  22. Section 2: Epidemiological data of COVID-19 (from DOI: 10.1016/j.clim.2020.108427)
  23. Section 2: IFNs as natural broad-spectrum antivirals (from DOI: 10.1084/jem.20200653)
  24. Section 2: Is SARS-CoV-2 a congenital or perinatally-acquired pathogen for the neonate? (from DOI: 10.1016/j.jcv.2020.104372)
  25. Section 2: Methods (from DOI:10.14218/ERHM.2020.00023)
  26. Section 2: Methods (from DOI: 10.1016/j.adro.2020.04.015)
  27. Section 2: Protection requirements of medical personnel (from DOI: 10.1080/22221751.2020.1735265)
  28. Section 2: SARS-CoV-2 Biology and Clinical Implications (from DOI: 10.1007/s11886-020-01293-2)
  29. Section 2: The concept of CSCs (from DOI: 10.1038/s41392-020-0110-5)
  30. Section 3.1.1: Myocardial Injury and Heart Failure (from DOI: 10.1007/s11886-020-01293-2)
  31. Section 3.1.2: Arrhythmia (from DOI: 10.1007/s11886-020-01293-2)
  32. Section 3.1. Metagenomic Approach (from DOI: 10.3390/v12020211)
  33. Section 3.1: Cardiac Complications of COVID-19 (from DOI: 10.1007/s11886-020-01293-2)
  34. Section 3.1: Major transcription factors in CSCs (from DOI: 10.1038/s41392-020-0110-5)
  35. Section 3.1: Screening criteria (from DOI: 10.1080/22221751.2020.1735265)
  36. Section 3.2.1: Wnt signaling pathway in CSCs (from DOI: 10.1038/s41392-020-0110-5)
  37. Section 3.2.2: Notch signaling pathway in CSCs (from DOI: 10.1038/s41392-020-0110-5)
  38. Section 3.2.3: Hh signaling pathway in CSCs (from DOI: 10.1038/s41392-020-0110-5)
  39. Section 3.2.4: NF-kappaB signaling pathway in CSCs (from DOI: 10.1038/s41392-020-0110-5)
  40. Section 3.2.5: JAK-STAT signaling pathway (from DOI: 10.1038/s41392-020-0110-5)
  41. Section 3.2.6: TGF/SMAD signaling pathway in CSCs (from DOI: 10.1038/s41392-020-0110-5)
  42. Section 3.2.7: PI3K/AKT/mTOR signaling pathway in CSCs (from DOI: 10.1038/s41392-020-0110-5)
  43. Section 3.2.7PI3K/AKT/mTOR signaling pathway in CSCs (from DOI: 10.1038/s41392-020-0110-5)
  44. Section 3.2.8: PPAR signaling pathways in CSCs (from DOI: 10.1038/s41392-020-0110-5)
  45. Section 3.2.9: Interactions between signaling pathways in CSCs (from DOI: 10.1038/s41392-020-0110-5)
  46. Section 3.2. Problems of Metagenomic Approach (from DOI: 10.3390/v12020211)
  47. Section 3.2: Diagnostic criteria (from DOI: 10.1080/22221751.2020.1735265)
  48. Section 3.2: Major signaling pathways in CSCs (from DOI: 10.1038/s41392-020-0110-5)
  49. Section 3.3.1. Nucleic Acids Depletion (from DOI: 10.3390/v12020211)
  50. Section 3.3.1: Screening cases on the day of visit (from DOI: 10.1080/22221751.2020.1735265)

View (previous 50 | next 50) (20 | 50 | 100 | 250 | 500)

Retrieved from "http://wikibase.slis.ua.edu/wiki/Special:WithoutInterwiki"